State of the Art Review on the Treatment of Psoriatic Disease.

Q4 Medicine Mediterranean Journal of Rheumatology Pub Date : 2024-01-31 eCollection Date: 2024-03-01 DOI:10.31138/mjr.040123.sot

Eleftherios Pelechas, Evripidis Kaltsonoudis, Michalis P Migkos, Nikolaos Koletsos, Panagiota G Karagianni, Alexandros A Drosos, Paraskevi V Voulgari

{"title":"State of the Art Review on the Treatment of Psoriatic Disease.","authors":"Eleftherios Pelechas, Evripidis Kaltsonoudis, Michalis P Migkos, Nikolaos Koletsos, Panagiota G Karagianni, Alexandros A Drosos, Paraskevi V Voulgari","doi":"10.31138/mjr.040123.sot","DOIUrl":null,"url":null,"abstract":"Introduction: Psoriasis is an inflammatory skin disease that in some cases is accompanied by systemic manifestations. Given the varied clinical manifestations, the term psoriatic disease probably better reflects the clinical picture of these patients.Literature review: In most cases, the skin lesions precede joint involvement as well as other potentially involved organs such as the intestine and the eye. Various immune-mediated cellular pathways such as that of TNFα, IL-23, IL-17 as well as other cytokines are involved in the pathophysiology of the psoriatic disease.Future insights: A better understanding of the way they interfere with our immune system has led to remarkably better disease control and outcomes. This review aims to highlight the newest treatments for psoriatic disease, which are expected to significantly reduce unmet needs and treatment gaps.","PeriodicalId":32816,"journal":{"name":"Mediterranean Journal of Rheumatology","volume":"35 1","pages":"66-72"},"PeriodicalIF":0.0000,"publicationDate":"2024-01-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11082764/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Mediterranean Journal of Rheumatology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.31138/mjr.040123.sot","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Psoriasis is an inflammatory skin disease that in some cases is accompanied by systemic manifestations. Given the varied clinical manifestations, the term psoriatic disease probably better reflects the clinical picture of these patients.

Literature review: In most cases, the skin lesions precede joint involvement as well as other potentially involved organs such as the intestine and the eye. Various immune-mediated cellular pathways such as that of TNFα, IL-23, IL-17 as well as other cytokines are involved in the pathophysiology of the psoriatic disease.

Future insights: A better understanding of the way they interfere with our immune system has led to remarkably better disease control and outcomes. This review aims to highlight the newest treatments for psoriatic disease, which are expected to significantly reduce unmet needs and treatment gaps.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

银屑病治疗现状综述。

简介银屑病是一种炎症性皮肤病，在某些情况下伴有全身表现。鉴于其临床表现多种多样，银屑病一词或许更能反映这些患者的临床表现：在大多数情况下，皮肤病变先于关节受累以及其他可能受累的器官，如肠道和眼睛。各种免疫介导的细胞通路，如 TNFα、IL-23、IL-17 以及其他细胞因子，都参与了银屑病的病理生理学过程：对细胞因子干扰免疫系统的方式有了更深入的了解后，疾病控制和治疗效果明显改善。本综述旨在重点介绍银屑病的最新疗法，这些疗法有望大大减少尚未满足的需求和治疗差距。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊